MK-571 sodium salt hydrate
SIGMA/M7571 - ≥95% (HPLC)
Synonym: 5-
CAS Number: 115103-85-0 (anhydrous)
Empirical Formula (Hill Notation): C26H26ClN2NaO3S2 · xH2O
Molecular Weight: 537.07 (anhydrous basis)
MDL Number: MFCD11114392
Linear Formula: C26H26ClN2NaO3S2 · xH2O
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: M7571-25MG
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: M7571-5MG
| assay | ≥95% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C26H27ClN2O3S2.Na.H2O/ |
| InChI key | MSHRPLRGSQECLY-DOLBFOAYSA |
| originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| Quality Level | 100  |
| shipped in | wet ice |
| SMILES string | O.[Na+].CN(C)C(=O)CCSC(SC |
| solubility | H2O: 15 mg/mL, clear |
| storage condition | desiccated |
| storage temp. | −20°C |
| Application: | MK-571 sodium salt hydrate has been used: • as an efflux inhibitor for monitoring multidrug resistance protein (MRP)-function and to avoid redundancy of other transporters • to assess its effect on cell proliferation and 2D-migration in vitro in various cell lines of glioblastoma multiforme (GBM) • as multidrug resistance (MDR) transporter inhibitor to study its effects in ovarian cancer cells • as specific inhibitors of ABCC1/2 to investigate transport, toxicity, flow cytometry and arsenic efflux |
| Biochem/physiol Actions: | MK 571 is a potent and selective leukotriene D4 (LTD4) antagonist and ABCC multidrug resistance protein 1(MRP1) inhibitor. The cysteinyl leukotrienes (CysLTs), LTC4, LTD4, and LTE4, mediate their actions through two distinct G-protein coupled receptors. LTD4 is the preferred ligand for the CysLT1 receptor, whereas LTC4 and LTD4 bind with approximately equal affinity to the CysLT2 receptor. MK 571 is a selective, orally active CysLT1 receptor antagonist. It blocks the binding of LTD4, but not LTC4, to human and guinea pig lung membranes with Ki values of 0.22 nM and 2.1 nM, respectively. MK 571 effectively blocks LTD4 activation of recombinant human and mouse CysLT1 receptors but is ineffective at blocking LTC4 or LTD4 activation of the recombinant human or murine CysLT2 receptors. It potentially inhibits MRP1 and has been shown to overcome acquired arsenic tolerance. |
| Biochem/physiol Actions: | MK-571 is a potent and selective leukotriene D4 (LTD4) antagonist and ABCC multidrug resistance protein 1(MRP1) inhibitor. |
| Features and Benefits: | This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 51111800 |